ライフサイエンスコーパス: pomalidomide

1 the immunomodulatory drugs lenalidomide and pomalidomide.

2 mplex bound to thalidomide, lenalidomide and pomalidomide.

3 e sensitive or resistant to lenalidomide and pomalidomide.

4 c activity of another immunomodulatory drug, pomalidomide.

5 on with the IMiD derivatives lenalidomide or pomalidomide.

6 GDC-0853 and the cereblon recruitment ligand pomalidomide.

7 inant negative Cullin 4A mutant, and by free pomalidomide.

8 38 refractory disease or previously received pomalidomide.

9 d by the anti-myeloma drugs lenalidomide and pomalidomide.

10 17, to the cereblon (CRBN) E3 ligase ligand, pomalidomide.

11 phase 2 dose for indatuximab ravtansine plus pomalidomide.

12 r treatment with HbF inducers hydroxyurea or pomalidomide.

13 with a higher affinity than lenalidomide or pomalidomide.

14 oidosis responding to salvage treatment with pomalidomide.

15 nation of immunotherapy with lenalidomide or pomalidomide.

16 Pomalidomide 0.5 mg per day is a safe and effective ther

17 cebo, pomalidomide (2 mg/d) plus prednisone, pomalidomide (0.5 mg/d) plus prednisone, and prednisone

18 Three patients received pomalidomide 2 mg/d with no dose-limiting toxicity.

19 n study, four treatment arms were evaluated: pomalidomide (2 mg/d) plus placebo, pomalidomide (2 mg/d

20 aluated: pomalidomide (2 mg/d) plus placebo, pomalidomide (2 mg/d) plus prednisone, pomalidomide (0.5

21 7 (27%) received indatuximab ravtansine plus pomalidomide (24.1 months [17.7-36.7]).

22 kly for 4 weeks, followed by every 2 weeks), pomalidomide 4 mg (days 1-21), and dexamethasone 40 mg (

23 16 mg/kg at the recommended dosing schedule, pomalidomide 4 mg daily for 21 days of each 28-day cycle

24 s of pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, and dexamethasone 4

25 Patients received oral pomalidomide 4 mg daily on days 1-21 and oral low-dose d

26 Patients were randomized (1:1) to receive pomalidomide 4 mg on days 1 to 21 of a 28-day cycle in c

27 Both groups received oral pomalidomide 4 mg on days 1-21 of each cycle, and weekly

28 in the pomalidomide group, patients received pomalidomide 4 mg orally daily on days 1 to 21 of each c

29 data from other phase 2 trials, suggest that pomalidomide 4 mg per day on days 1 to 21 of 28 with dex

30 Pomalidomide 4 mg per day on days 1 to 21 of each 28-day

31 nts (1:1) to either isatuximab 10 mg/kg plus pomalidomide 4 mg plus dexamethasone 40 mg (20 mg for pa

32 mg (20 mg for patients aged >=75 years), or pomalidomide 4 mg plus dexamethasone 40 mg.

33 Pomalidomide 4 mg was given on days 1-21 of 28-day cycle

34 was dose level 1 (carfilzomib 20/27 mg/m(2), pomalidomide 4 mg, dexamethasone 40 mg).

35 5 mg/kg intravenously every 21 days, or oral pomalidomide 4.0 mg daily (days 1-21) and dexamethasone

36 ned the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 2

37 In phase 1, dose level 1 consisted of pomalidomide (4 mg by mouth on days 1 to 21), IV or subc

38 day 1 of cycle 2 onward) combined with oral pomalidomide (4 mg on days 1 to 21) and oral dexamethaso

39 Oral pomalidomide (4 mg once daily; days 1-21) and dexamethas

40 Pomalidomide (4 mg) was given orally on days 1 to 21 (ar

41 All patients received oral pomalidomide (4 mg, once daily on days 1-21) and oral de

42 Blood, Dulmovits and colleagues report that pomalidomide, a drug approved by the US Food and Drug Ad

43 linking the antibiotic trimethoprim (TMP) to pomalidomide, a ligand for the E3 ligase, Cereblon.

44 Pomalidomide, a third-generation immunomodulatory drug,

45 Pomalidomide, a widely used E3 ligase recruiter in PROTA

46 CL subtypes and showed greater efficacy than pomalidomide across 4 in vivo TCL models.

47 Pomalidomide acted early by transiently delaying erythro

48 o our knowledge, the first phase II trial of pomalidomide administered in combination with low-dose d

49 ere show that thalidomide, lenalidomide, and pomalidomide affect stem cell mesendoderm differentiatio

50 nd switch-off CRISPR-based technologies with pomalidomide allowed complete control over their activit

51 rable pharmacological attributes of the drug pomalidomide allowed control of activity of base editor

52 indicated that vactosertib co-treatment with pomalidomide also reduced TGFbeta levels in patient bone

53 We evaluated pomalidomide, an oral immune modulatory agent, in patien

54 zation; 95 patients were assigned to receive pomalidomide and 49 to receive placebo.

55 lines of therapy, including lenalidomide or pomalidomide and a proteasome inhibitor, were enrolled i

56 and systemic antiangiogenic drugs including pomalidomide and bevacizumab for moderate-to-severe blee

57 nts treated with indatuximab ravtansine with pomalidomide and dexamethasone (indatuximab ravtansine p

58 rial, we assessed the safety and efficacy of pomalidomide and dexamethasone (PDex) in patients with A

59 Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated i

60 lufen and dexamethasone (melflufen group) or pomalidomide and dexamethasone (pomalidomide group).

61 risk of disease progression or death versus pomalidomide and dexamethasone alone and could be consid

62 random block size of two or four to receive pomalidomide and dexamethasone alone or daratumumab plus

63 Combination studies using pomalidomide and dexamethasone are now underway.

64 ays 1 and 8 of cycle 9 onward) combined with pomalidomide and dexamethasone at the same doses and sch

65 The combination of pomalidomide and dexamethasone can be safely administere

66 ion-free survival benefit of isatuximab plus pomalidomide and dexamethasone compared with pomalidomid

67 group versus 23.7 months (19.6-29.4) in the pomalidomide and dexamethasone group (hazard ratio [HR]

68 progression-free survival compared with the pomalidomide and dexamethasone group (median 12.4 months

69 omide and dexamethasone group (n=125) or the pomalidomide and dexamethasone group (n=124).

70 ly assigned to either the pembrolizumab plus pomalidomide and dexamethasone group (n=125) or the poma

71 re randomly assigned to the daratumumab plus pomalidomide and dexamethasone group (n=151) or the poma

72 omide and dexamethasone group (n=151) or the pomalidomide and dexamethasone group (n=153).

73 ed deaths occurred in the pembrolizumab plus pomalidomide and dexamethasone group (one each of unknow

74 ndomly assigned: 151 to the daratumumab plus pomalidomide and dexamethasone group and 153 to the poma

75 54%) of 149 patients in the daratumumab plus pomalidomide and dexamethasone group and in 60 (40%) of

76 domly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide

77 The daratumumab plus pomalidomide and dexamethasone group received daratumuma

78 months (IQR 14.4-20.6), the daratumumab plus pomalidomide and dexamethasone group showed improved pro

79 s (95% CI 23.7-40.3) in the daratumumab plus pomalidomide and dexamethasone group versus 23.7 months

80 %) of 120 patients in the pembrolizumab plus pomalidomide and dexamethasone group versus 56 (46%) of

81 50%) of 149 patients in the daratumumab plus pomalidomide and dexamethasone group versus 59 (39%) of

82 s (95% CI 3.7-7.5) in the pembrolizumab plus pomalidomide and dexamethasone group versus 8.4 months (

83 pomalidomide and dexamethasone group or the pomalidomide and dexamethasone group via an interactive

84 68%] of 149 patients in the daratumumab plus pomalidomide and dexamethasone group vs 76 [51%] of 150

85 one group vs 76 [51%] of 150 patients in the pomalidomide and dexamethasone group), anaemia (25 [17%]

86 group and in 60 (40%) of 150 patients in the pomalidomide and dexamethasone group, the most common of

87 omide and dexamethasone group and 153 to the pomalidomide and dexamethasone group.

88 reatment-related deaths were reported in the pomalidomide and dexamethasone group.

89 group versus 56 (46%) of 121 patients in the pomalidomide and dexamethasone group.

90 group versus 59 (39%) of 150 patients in the pomalidomide and dexamethasone group; pneumonia (23 [15%

91 p versus 8.4 months (5.9-not reached) in the pomalidomide and dexamethasone group; progression-free s

92 udy assessing two different dose regimens of pomalidomide and dexamethasone in advanced MM.

93 eagues(2) publish two different trials using pomalidomide and dexamethasone in patients with relapsed

94 tinue to support the use of daratumumab plus pomalidomide and dexamethasone in patients with relapsed

95 pomalidomide and dexamethasone compared with pomalidomide and dexamethasone in patients with relapsed

96 phase 1b study, intravenous daratumumab plus pomalidomide and dexamethasone induced a very good parti

97 Pomalidomide and dexamethasone is a standard of care for

98 e benefit-risk profile of pembrolizumab plus pomalidomide and dexamethasone is unfavourable for patie

99 n patients (1:1) to receive daratumumab plus pomalidomide and dexamethasone or pomalidomide and dexam

100 efractory multiple myeloma, daratumumab plus pomalidomide and dexamethasone reduced the risk of disea

101 ed in 44 refractory MM patients treated with pomalidomide and dexamethasone therapy in whom low IKZF1

102 KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or without pembroliz

103 ons for adverse reactions were permitted for pomalidomide and dexamethasone, but not for isatuximab.

104 and dexamethasone alone or daratumumab plus pomalidomide and dexamethasone.

105 mumab plus pomalidomide and dexamethasone or pomalidomide and dexamethasone; patients were stratified

106 e believe to be a new mechanism of action of pomalidomide and lenalidomide and support the hypothesis

107 e new insights on the mechanism of action of pomalidomide and lenalidomide in the regulation of gene

108 on our findings, we propose a model in which pomalidomide and lenalidomide modify the chromatin struc

109 We tested the effect of Pomalidomide and Lenalidomide on angiogenesis, teratogen

110 demethylase-1 (LSD1) silencing reduced both pomalidomide and lenalidomide up-regulation of p21(WAF-1

111 ves of thalidomide (IMiD compounds), such as pomalidomide and lenalidomide, are highly active in mult

112 The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) can be

113 Pomalidomide and low-dose dexamethasone (PomDex) is stan

114 The combination of pomalidomide and low-dose dexamethasone is extremely act

115 sponse with a combination of isatuximab with pomalidomide and low-dose dexamethasone.

116 Our data indicate antifibrotic effects of pomalidomide and possible association with increases in

117 Using pomalidomide and primary human monocytes, we report that

118 reactions with E3 ligase recruiters such as pomalidomide and related derivatives provide new degrade

119 etermine the maximum tolerated dose (MTD) of pomalidomide and to explore its efficacy when combined w

120 When combined with hydroxyurea, pomalidomide and, to a lesser extent, lenalidomide were

121 immunomodulators (lenalidomide, thalidomide, pomalidomide and/or methotrexate) in the past month.

122 ng immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors.

123 ith at least two lines of therapy (excluding pomalidomide) and refractory to the last line were rando

124 l blood during treatment with durvalumab and pomalidomide, and combination therapy induced significan

125 el trial, we evaluated belantamab mafodotin, pomalidomide, and dexamethasone (BPd), as compared with

126 erapeutic regimen consisting of carfilzomib, pomalidomide, and dexamethasone (CPD) in an open-label,

127 In the DREAMM-8 trial, belantamab mafodotin, pomalidomide, and dexamethasone demonstrated a statistic

128 ogression or death compared with bortezomib, pomalidomide, and dexamethasone in lenalidomide-exposed

129 e myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone or bortezomib, pomalidom

130 malidomide, and dexamethasone or bortezomib, pomalidomide, and dexamethasone reported stable HRQOL.

131 l (n=254) or standard regimens (daratumumab, pomalidomide, and dexamethasone; daratumumab, bortezomib

132 arfilzomib and dexamethasone; or elotuzumab, pomalidomide, and dexamethasone; n=132).

133 cells/kg) or standard of care (daratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomi

134 ory imide drugs (IMiDs) such as thalidomide, pomalidomide, and lenalidomide are the most common cereb

135 Glutarimides such as thalidomide, pomalidomide, and lenalidomide are the most frequently u

136 Pembrolizumab, pomalidomide, and low-dose dexamethasone have acceptable

137 We conclude that pomalidomide appears to be a valuable drug covering an u

138 unomodulatory drugs (IMiDs) lenalidomide and pomalidomide are Food and Drug Administration-approved d

139 and its structural analogs lenalidomide and pomalidomide are highly effective in treating clinical i

140 unomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multipl

141 Lenalidomide and pomalidomide are members of a class of immunomodulators

142 revealed that everolimus, temsirolimus, and pomalidomide are predicted to target the calcificasome.

143 These findings support further evaluation of pomalidomide as a novel therapy for SCD.

144 This work has implications for Pomalidomide as a treatment for conditions Thalidomide a

145 These findings support the evaluation of pomalidomide as an innovative new therapy for beta-hemog

146 Pomalidomide at doses of 2 or 4 mg/d has demonstrated ex

147 t to hydroxyurea's myelosuppressive effects, pomalidomide augmented erythropoiesis and preserved bone

148 we selected three compounds: (a) a Ro5 drug (Pomalidomide), (b) a bRo5 orally available drug (Saquina

149 f-target degradation and found that reported pomalidomide-based PROTACs induce degradation of several

150 The drugs lenalidomide and pomalidomide bind to the protein cereblon, directing the

151 (2%) were recorded in patients who received pomalidomide, bortezomib, and dexamethasone (pneumonia [

152 mum tolerated doses, safety, and efficacy of pomalidomide, bortezomib, and dexamethasone (PVD) combin

153 e, and dexamethasone (BPd), as compared with pomalidomide, bortezomib, and dexamethasone (PVd), in le

154 278 patients received at least one dose of pomalidomide, bortezomib, and dexamethasone and 270 pati

155 281 patients were assigned pomalidomide, bortezomib, and dexamethasone and 278 were

156 This study supports use of pomalidomide, bortezomib, and dexamethasone as a treatme

157 progression-free survival when treated with pomalidomide, bortezomib, and dexamethasone compared wit

158 The combination of pomalidomide, bortezomib, and dexamethasone has shown pr

159 Pomalidomide, bortezomib, and dexamethasone significantl

160 how pharmacologic agents (eg, lenalidomide, pomalidomide, bortezomib, and dexamethasone) and autolog

161 aratumumab, pomalidomide, and dexamethasone; pomalidomide, bortezomib, and dexamethasone).

162 nts accorded with the individual profiles of pomalidomide, bortezomib, and dexamethasone.

163 me highly resistant to both lenalidomide and pomalidomide, but not to the unrelated drugs bortezomib,

164 han double that observed with decitabine and pomalidomide; butyrate had an intermediate effect wherea

165 ently developed and offer new possibilities (pomalidomide, carfilzomib and ixazomib, panobinostat, el

166 second zinc finger of SALL4 in complex with pomalidomide, cereblon and DDB1 reveals the molecular de

167 vitro experiments indicated that vactosertib+pomalidomide co-treatment decreased the viability of MM

168 Our results indicate that pomalidomide could be used to decrease fibrogenesis in p

169 Pomalidomide-cyclophosphamide-prednisone is safe and eff

170 re to bortezomib, carfilzomib, lenalidomide, pomalidomide, daratumumab, and an alkylating agent and h

171 over, multiple myeloma patients treated with pomalidomide demonstrated increased in vivo gamma-globin

172 ere, we show that the immunomodulatory agent pomalidomide depletes pancreatic lesion areas of alterna

173 ination with weekly dexamethasone (arm B) or pomalidomide, dexamethasone, and cyclophosphamide (PomCy

174 lidomide-dexamethasone (isatuximab group) or pomalidomide-dexamethasone (control group).

175 amab mafodotin and 7.0 months (4.6-10.6) for pomalidomide-dexamethasone (hazard ratio 1.03 [0.72-1.47

176 and aged (<75 vs >=75 years), to isatuximab-pomalidomide-dexamethasone (isatuximab group) or pomalid

177 clonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone

178 nce in median overall survival compared with pomalidomide-dexamethasone and is a new standard of care

179 methasone group (sepsis) and two (1%) in the pomalidomide-dexamethasone group (pneumonia and urinary

180 rted for one patient (<1%) in the isatuximab-pomalidomide-dexamethasone group (sepsis) and two (1%) i

181 ported in 12 patients (8%) in the isatuximab-pomalidomide-dexamethasone group and 14 (9%) in the poma

182 The isatuximab-pomalidomide-dexamethasone group received isatuximab int

183 5 months (95% CI 8.9-13.9) in the isatuximab-pomalidomide-dexamethasone group versus 6.5 months (4.5-

184 he belantamab mafodotin group and 107 to the pomalidomide-dexamethasone group); 184 (57%) of 325 were

185 omide-dexamethasone group and 14 (9%) in the pomalidomide-dexamethasone group.

186 one group versus 6.5 months (4.5-8.3) in the pomalidomide-dexamethasone group; hazard ratio 0.596, 95

187 Addition of isatuximab plus pomalidomide-dexamethasone resulted in a 6.9-month diffe

188 The addition of isatuximab to pomalidomide-dexamethasone significantly improves progre

189 ergent adverse events (any grade; isatuximab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone

190 de; isatuximab-pomalidomide-dexamethasone vs pomalidomide-dexamethasone) were infusion reactions (56

191 307 patients to treatment: 154 to isatuximab-pomalidomide-dexamethasone, and 153 to pomalidomide-dexa

192 mab mafodotin and 10.8 months (5.6-17.1) for pomalidomide-dexamethasone.

193 (34 [33%] of 102) and anaemia (18[18%]) for pomalidomide-dexamethasone.

194 ximab-pomalidomide-dexamethasone, and 153 to pomalidomide-dexamethasone.

195 manageable safety profile of isatuximab plus pomalidomide/dexamethasone in heavily pretreated patient

196 tinuous or intermittent dosing strategies of pomalidomide/dexamethasone in lenalidomide-refractory my

197 e-escalation study evaluated isatuximab plus pomalidomide/dexamethasone in patients with relapsed/ref

198 We found that Pomalidomide, displays a high degree of cell specificity

199 atory drug (IMiD) analogs, lenalidomide, and pomalidomide, dose-dependently inhibited hiPSC mesendode

200 he clinical and pharmacodynamics analysis of pomalidomide dosing strategies in multiple myeloma (MM)

201 inhibition in combination with lenalidomide/pomalidomide, double autologous stem cell transplant plu

202 onal or investigational (eg, JAK inhibitors, pomalidomide) drug therapy, allogenic stem cell transpla

203 The pomalidomide effect on actin cytoskeleton was blocked by

204 the activation of Rho GTPases, we found that pomalidomide enhanced F-actin formation, stabilized micr

205 0 [76%] of 249 patients had an event) in the pomalidomide group (hazard ratio [HR] 0.79, [95% CI 0.64

206 0-72]; 107 [43%] were female) and 249 to the pomalidomide group (median age 68 years [IQR 61-72]; 109

207 te cardiac failure) and four patients in the pomalidomide group (two patients with pneumonia, one wit

208 At 24 weeks, the mean difference between the pomalidomide group and the placebo group in the change f

209 up and 25.0 months (95% CI 18.1-31.9) in the pomalidomide group at a median follow-up of 18.6 months

210 s in the melflufen group and 32 [13%] in the pomalidomide group had fatal treatment-emergent adverse

211 e dose of study drug (melflufen group n=228; pomalidomide group n=246; safety population).

212 Adverse events that were more common in the pomalidomide group than in the placebo group included ne

213 he melflufen group vs 26 [11%] of 246 in the pomalidomide group), neutropenia (123 [54%] vs 102 [41%]

214 en group) or pomalidomide and dexamethasone (pomalidomide group).

215 ver 30 min on day 1 of each cycle and in the pomalidomide group, patients received pomalidomide 4 mg

216 in the melflufen group and 113 (46%) in the pomalidomide group, the most common of which were pneumo

217 patients in the indatuximab ravtansine plus pomalidomide group.

218 fen group and 16.3 months (10.1-23.2) in the pomalidomide group.

219 global sales, nivolumab, pembrolizumab, and pomalidomide had the lowest eligibility rates for data s

220 d dexamethasone (indatuximab ravtansine plus pomalidomide) had failure of at least two previous thera

221 An additional analog, Pomalidomide, has recently been licensed for treatment o

222 Lenalidomide and pomalidomide have both been evaluated clinically for the

223 drugs (IMiDs) thalidomide, lenalidomide, and pomalidomide have revolutionized the treatment of patien

224 and immunomodulatory drugs (lenalidomide or pomalidomide) have shown promising clinical response rat

225 idomide and its derivatives lenalidomide and pomalidomide (IMiDs) are effective treatments of haemato

226 Pomalidomide in combination with weekly dexamethasone (P

227 and cereblon/ikaros in antitumor effects of pomalidomide in vivo is unknown.

228 domide analogues, including lenalidomide and pomalidomide, in the treatment of haematological maligna

229 e selectively and differentially affected by pomalidomide including BCL11A, SOX6, IKZF1, KLF1, and LS

230 dulatory (IMiD) agents like lenalidomide and pomalidomide induce the recruitment of IKZF1 and other t

231 Here, we report that pomalidomide induced a fetal-like erythroid differentiat

232 We found that 8 weeks of treatment with pomalidomide induced modest increases of HbF with simila

233 Pomalidomide induced poly-functional T-cell activation,

234 Pomalidomide-induced absence of alternatively activated

235 hat the activation of RhoA was essential for pomalidomide-induced interleukin-2 expression in T cells

236 Notably, the pomalidomide-induced reprogramming was conserved in hema

237 In addition, they show that pomalidomide induces HbF in differentiating erythroid ce

238 Pomalidomide is a new IMiD with high in vitro potency.

239 Pomalidomide is a potent structural analog of thalidomid

240 We demonstrate that in vivo embryonic assays Pomalidomide is a significantly more potent anti-inflamm

241 Conclusion Pomalidomide is well tolerated and active in KS regardle

242 atients) and for indatuximab ravtansine plus pomalidomide it was 88% (15 of 17 patients).

243 e antimyeloma cellular immunity generated by pomalidomide, leading to improved clinical responses.

244 These data demonstrate that pomalidomide leads to strong and rapid immunomodulatory

245 Pomalidomide led to rapid decline in Ikaros in T and NK

246 omide (LEN)-refractory and lenalidomide-then-pomalidomide (LEN-then-POM)-refractory timepoints.

247 In preclinical studies, pomalidomide mediated both direct antitumor effects and

248 inding transcription factors are involved in pomalidomide-mediated up-regulation of p21(WAF-1).

249 thalidomide (n=42), lenalidomide (n=18), or pomalidomide (n=18).

250 Both groups received oral pomalidomide on days 1 to 21 in each cycle, and oral or

251 We investigated the effects of pomalidomide on erythropoiesis and hemoglobin synthesis

252 investigated the effects of lenalidomide and pomalidomide on erythropoiesis and hemoglobin synthesis.

253 ry effects of thalidomide, lenalidomide, and pomalidomide on LPM differentiation while retaining sens

254 15, and 16 (starting dose of 20/27 mg/m(2)), pomalidomide once daily on days 1 to 21 (4 mg as the ini

255 Further, we showed that in Swiss 3T3 cells, pomalidomide only activated RhoA, not Rac1 or Cdc42, and

256 xic activity of anti-MM agents lenalidomide, pomalidomide or dexamethasone.

257 utic value of new drugs (eg, JAK inhibitors, pomalidomide) or allogeneic stem-cell transplantation.

258 Pomalidomide overcomes resistance in myeloma refractory

259 owed superior progression-free survival than pomalidomide plus dexamethasone in patients with relapse

260 present the largest trial to date evaluating pomalidomide plus low-dose dexamethasone in patients wit

261 TRATUS study assessed safety and efficacy of pomalidomide plus low-dose dexamethasone in the largest

262 Pomalidomide (Pom) was previously shown to increase immu

263 2 study assessed the efficacy and safety of pomalidomide (POM) with/without low-dose dexamethasone (

264 other day, for 6 28-day cycles, followed by pomalidomide-prednisone maintenance therapy.

265 Specifically, we designed a folate-caged pomalidomide prodrug, FA-S2-POMA, by incorporating a fol

266 and primary human monocytes, we report that pomalidomide rapidly and selectively activated RhoA and

267 ata reveal the molecular mechanisms by which pomalidomide reactivates fetal hemoglobin, reinforcing i

268 Patients allocated pomalidomide received 4 mg orally on days 1-14.

269 drugs such as thalidomide, lenalidomide, and pomalidomide, recognizes an acetyl degron of GS, resulti

270 Recent reports demonstrated that pomalidomide reduced or eliminated transfusion requireme

271 ti-programmed cell death protein 1 (PD1) and pomalidomide reduced the T-cell exhaustion that occurs i

272 ffector cereblon (CRBN) by the time they are pomalidomide refractory.

273 modulatory drugs, including lenalidomide and pomalidomide represent a novel class of small molecule a

274 ew agents, such as the third-generation IMiD pomalidomide, the second-generation PIs carfilzomib and

275 Pomalidomide therapy at 0.5 or 2 mg/d with or without an

276 idomide and its derivatives lenalidomide and pomalidomide, these immunomodulatory drugs (IMiDs) recen

277 ducing the E3 ligase cereblon-binding ligand pomalidomide to Mcl-1/Bcl-2 dual inhibitors S1-6 and Nap

278 nations adding 1 of these new agents (except pomalidomide) to the RD or VD regimens were superior to

279 Among patients with HHT, pomalidomide treatment resulted in a significant, clinic

280 Pomalidomide treatment resulted in downregulation of int

281 genetic ablation of IKZF1 did not phenocopy pomalidomide treatment.

282 lenalidomide and support the hypothesis that pomalidomide, used alone or in combination with hydroxyu

283 bortezomib and dexamethasone with or without pomalidomide using a permutated blocked design in blocks

284 Finally, we demonstrated that pomalidomide was able to regulate the activity of Rho GT

285 Pomalidomide was administered at 2 and 3 mg on days 1 to

286 Pomalidomide was administered continuously and dexametha

287 Pomalidomide was administered for up to 12 28-day treatm

288 Pomalidomide was given at 1 to 2.5 mg/d, cyclophosphamid

289 Pomalidomide was given orally 2 or 4 mg daily with dexam

290 Pomalidomide was shown to be even more effective in refr

291 IKAROS (IKZF1), a known target of pomalidomide, was degraded by the proteasome, but was no

292 Pomalidomide, which degrades IKZF1 and IKZF3, induced IF

293 the second-generation immunomodulatory drug pomalidomide, which was recently approved by the US Food

294 t correlation of immune effects triggered by pomalidomide with clinical responses in MM patients.

295 The objectives of a phase 1/2 trial of pomalidomide with dexamethasone for the treatment of lig

296 ders versus nonresponders to durvalumab plus pomalidomide with dexamethasone therapy.

297 Response to pomalidomide with or without prednisone was durable (ran

298 opened 2 sequential phase 2 trials using the pomalidomide with weekly dexamethasone (Pom/dex) regimen

299 alumab as monotherapy or in combination with pomalidomide with/without dexamethasone were characteriz

300 unomodulatory drugs (IMiDs) lenalidomide and pomalidomide yield high response rates in patients with